CONTRAINDICATIONS According to the package insert, Wegovy is contraindicated in patients with the following: personal or family history of Medullary Thyroid Carcinoma patients with Multiple Endocrine Neoplasm type 2 patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy
By binding to GLP-1 receptors in the brain, semaglutide reduces appetite and food intake
Cardiovascular Benefits: One of the standout features of Semaglutide is its cardiovascular benefits
If symptoms are new, severe, or accompanied by swelling, rash, or wheeze, seek urgent evaluation
Most patients do not see significant weight loss or substantial glucose control improvements in the first 48 hours
No, standard semaglutide doses range from 0.25 mg to 2 mg